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Abstract Nuclear receptors (NRs) are a large family of ligand-dependent 
 transcriptional regulators that control development, reproduction, metabolism, and 
inflammation. Cognate ligands include fatty acids, bile acids, steroids, vitamins A 
and D, and thyroid hormone, which enable NRs to sense lipophilic nutrients levels 
and control their respective flux and metabolism. While major metabolic outputs of 
some individual receptors are well studied, an integrated understanding of their 
contributions to systemic metabolic homeostasis is just starting to be revealed. In 
this chapter, we summarize recent advances in NR signaling in metabolism, with a 
focus on the emerging paradigm that positions NRs as hubs that translate environ-
mental signals of a particular physiological state into daily metabolic rhythms. As 
NRs are a proven class of therapeutic targets, these novel findings provide insight 
into therapeutics for the metabolic syndrome.
Keywords Nuclear receptors • Energy homeostasis • Metabolite signaling • 
Microbiome • FGFs • Metabolic diseases
 Introduction
The human body maintains relatively stable levels of key energy substrates through 
metabolic flexibility [1]. After a meal, elevated blood glucose triggers insulin 
release to facilitate glucose uptake in the liver and muscles while simultaneously 
suppressing free fatty acid release from adipose tissue. Between meals, a complex 
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counter-regulatory hormonal network maintains a steady blood glucose level via 
hepatic glycogen breakdown and gluconeogenesis while concurrently decreasing 
circulating insulin levels to allow adipose tissue lipolysis to release free fatty acids 
as the major source of energy. Hence, metabolic flexibility can also be described as 
the ability to switch between carbohydrates and lipids as the predominant source of 
energy [1].
While metabolic flexibility undoubtedly provided a survival advantage during 
our early hunter–gatherer times, in combination with excess nutrients it is now 
 driving the human body to a crisis point. Obesity is now a worldwide epidemic and 
is often accompanied by pathologies such as type 2 diabetes, hepatosteatosis, and 
cardiovascular diseases. The excessive accumulation of lipids in tissues brought 
about by modern day excess nutrient uptake, a condition termed as lipotoxicity [2], 
often results in insulin resistance and hyperglycemia, and leads to metabolic inflex-
ibility of the body.
At the cellular level, metabolic flexibility utilizes energy sensors, among which 
are nuclear receptors (NRs), that either activate or inhibit specific metabolic 
 pathways. NRs in humans are comprised of a family of 48 ligand-dependent 
 transcription factors with conserved molecular architecture that includes a DNA-
binding domain and a ligand-binding domain [3]. Ligands for NRs consist of a 
diverse array of small lipophilic molecules [3], which, upon binding to their cognate 
NR, recruit enzymatic cofactors to modulate their target gene expression and, 
thereby, physiological output. A small subset of NRs have been identified as major 
players in the maintenance of metabolic flexibility via their ability to sense key 
lipophilic dietary nutrients and regulate a complex network of genes to control the 
metabolic flux of these nutrients.
Intensive research over the past two decades has established the fundamental 
mode of action of a subset of individual receptors (Table 1), including the peroxi-
some proliferator-activated receptors (PPARs), farnesoid X receptor (FXR), and 
liver X receptors (LXRs). We will summarize the recent progress in elucidating how 
these receptors coordinate metabolic homeostasis in response to dietary intake and 
environmental stressors.
 NR Endogenous Ligands Are Dietary Sensors
The generation and degradation of prototypical endogenous NR ligands through 
enzymatic modifications, such as those catalyzed by cytochrome P450 (CYP) 
enzymes [3, 9], allows for integration with NR-independent regulatory pathways. 
For example, regulation of FOXO1 activity by hepatic insulin signaling determines 
the expression level of CYP7A1, the rate-limiting P450 enzyme in the synthesis of 
bile acids, the endogenous ligands for FXR [10].
In the case of the PPARs, each binds fatty acids with relatively low affinity and 
regulates metabolic homeostasis through canonical direct repeat 1 (DR1) elements 
within promoters and enhancers of target genes. Specificity is achieved at the level 
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Table 1 Nutrient-sensing nuclear receptors
Ligand Expression Function
PPARα Short-chain fatty 
acids
Liver PPARα was first identified as the 
target of the lipid-lowering drug 
phenofibrate. PPARα is a master 
regulator of the adaptive fasting 
response in the liver. In the fasted 
state, elevated circulating free fatty 
acids activate hepatic PPARα, 
whose targets include rate-limiting 
enzymes in fatty acid oxidation and 
ketogenesis [4]. PPARα knockout 
mice die upon prolonged fasting 







Adipose tissue PPARγ is the master regulator of 
adipogenesis and lipogenesis, and is 
required for both white and brown 
adipose tissue formation. 
Postprandial increase in fatty acids 
activates adipose PPARγ to facilitate 
fat storage and production of 
adipokines (leptin, adiponectin, 
resistin, etc.), which are important 
regulators of whole-body insulin 
sensitivity [4, 5]




PPARδ activation enhances fatty 
acid oxidation and mitochondrial 
respiration. PPARδ activation in 
white adipose tissue promotes its 
conversion to brown fat, whereas in 
the muscle, it increases oxidative 
type I fiber formation. In the liver, 
PPARδ controls fatty acid synthesis 
through direct activation of the 
rate-limiting enzyme Acaca [4, 6]
FXR Bile acids Liver, kidney, and 
intestine
FXR regulates bile acid homeostasis 
by promoting bile acid reabsorption 
in the gut and suppressing de novo 
bile acid synthesis in the liver [7, 8]
LXR Oxysterols LXRα: liver, 





LXRs promote cholesterol efflux in 
the liver via 3 mechanisms: 
(1) suppression of cholesterol uptake 
from LDL recycling; (2) production 
of VLDL for export; (3) conversion 
of cholesterol to bile acids for 
excretion. LXRs exert an opposing 
effect to FXR on bile acid 
metabolism [8]
Acaca acetyl-coA carboxylase 1, FXR farnesoid X receptor, LDL low-density lipoprotein, LXR 
liver X receptor, PPAR peroxisome proliferator-activated receptor, VLDL very low-density 
lipoprotein
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of the ligand, enabling the body to enact different physiological responses using 
common elements within the genome. Long-chain fatty acids preferentially activate 
PPARδ to stimulate fatty acid oxidation in skeletal muscle. In contrast, PPARα 
 activation by short-chain fatty acids switches on a feed-forward mechanism in the 
liver to promote fuel oxidation, thereby preventing the intracellular accumulation of 
fatty acids and consequent lipotoxicity. Thus, the coordinated actions of these 
PPARs protect against lipotoxicity through the regulation of different metabolic 
target tissues in response to the uptake of fatty acids.
 Gut and Gut Microbiota
There is growing evidence that the modern lifestyle, most notably the high-fat/high- 
sugar “Western” diet, has altered the genetic composition and metabolic activity of 
our resident microorganisms. The microbiome communicates with NRs through its 
ability to modify dietary nutrients to generate specific NR ligands. An early example 
is oleoylethanolamide (OEA), a high-affinity PPARα ligand generated in enterocytes 
from oleic acid [11]. OEA-induced activation of intestinal PPARα enhances fat 
absorption through induction of the target gene, CD36, and promotes satiety through 
a secondary signaling cascade in the brain [12].
More recently, an enhanced bile acid flux was observed throughout the intestinal 
tract of germ-free mice [13], suggestive of dysregulated FXR activity. While it was 
known that intestinal microbiota metabolize primary bile acids to increase their 
hydrophobicity and chemical diversity [13, 14], it was not known to what extent the 
microbiota influence FXR activity. The serum bile acid composition of the germ- 
free mice revealed elevated levels of tauro-conjugated alpha- and beta-muricholic 
acids (Tα/βMCA), known FXR antagonists [13, 15], which result in a loss of 
 feedback inhibition of bile acid synthesis. Importantly, this study demonstrates 
that endogenous FXR antagonists are default products of the canonical bile acid 
synthesis pathway, raising interesting questions about the co-evolution of crucial 
NR-dependent metabolic pathways and the intestinal microbiome.
An added biological complexity to this system is that reciprocally, bile acids can 
influence the composition of the intestinal microbiome. A diet high in saturated 
fatty acids increases tauro-conjugated cholic acid concentrations to promote the 
growth of sulfate-consuming bacteria, increasing the susceptibility of mice to colitis 
[16]. This dynamic relationship between bile acids and microbiota is still not well 
understood, making it difficult to predict the metabolic outcome when deregulation 
occurs. For example, while FXR null mice are more susceptible to metabolic disor-
ders [17–19], intestinal-specific FXR knockout mice are protected [15]. Clinically, 
the importance of this pathway was demonstrated in a recent study, which showed 
that the metabolic benefits of vertical sleeve gastrectomy were mediated by the gut 
microbiota and FXR signaling in the intestine [20].
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 De Novo Lipogenesis
In contrast to the relatively well-understood metabolic actions of dietary lipids, the 
effects of the largely monounsaturated fatty acids generated in the liver through 
de novo lipogenesis are now being explored [21]. Utilizing genetic mouse models 
to disrupt hepatic de novo lipogenesis, researchers have demonstrated a broad 
spectrum of metabolic changes on fat-free diets [22, 23]. Loss of fatty acid synthase 
(FAS)—a rate-limiting enzyme in de novo lipogenesis—in the liver leads to the 
development of a fatty liver upon fasting, similar to a PPARα knockout phenotype 
[24, 25]. Importantly, this fatty liver phenotype can be rescued with a PPARα 
synthetic ligand, implicating de novo fatty acid synthesis in the generation of 
endogenous PPARα ligands. Furthermore, the authors identified a phosphocholine 
(16:0/18:1-GPC) as an endogenous ligand for PPARα [24]. In adipose tissue, 
lipogenesis has been implicated in producing PPARγ endogenous ligands [26], such 
as 1-O-octadecenyl-2-palmitoyl-3-glycerophosphocholine (18:1e/16:0-GPC) [27].
Direct biochemical approaches have identified endogenous ligands for PPARα 
and PPARγ. How these ligands function in normal physiology when both dietary 
and de novo synthesized lipids are present is not clear [28]. Although not directly 
evaluated under diet-induced or genetic obesity, PC(16:0/18:1) is one of two serum 
phosphocholine species that were observed to have aberrant diurnal rhythmic 
 concentrations [29]. It should be cautioned that “ligands” identified through block-
ing of an endogenous pathway can be misleading, illustrated by the fact that these 
phospholipids are weak activators of their respective targets in cell-based reporter 
systems [24, 27]. However, weak pharmacological activation of PPARα or PPARγ 
is beneficial for some metabolic disorders, while, conversely, strong NR activators 
can carry significant side effects (e.g. rosiglitazone). It was recently shown that a 
weak PPARγ ligand could achieve similar therapeutic responses to rosiglitazone 
with limited side effects [30, 31]. Exploring the therapeutic values of these endog-
enous ligands will be an exciting next step.
 Integrative Physiology—Nuclear Receptor-Mediated 
Crosstalk
Metabolic flexibility results from cohesive actions of major metabolic organs in 
response to nutrient flux. It is a collective consequence of localized activation of 
cellular nutrient-sensing pathways and systemic hormonal actions. Whereas 
 hormones can be released from specialized endocrine organs that directly sense 
nutrients, they can also be produced from metabolic organs to amplify or propagate 
local nutrient cues. One example of the latter is the adipose PPARγ-mediated pro-
duction of adipokines such as leptin and adiponectin [5]. In the postprandial setting, 
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PPARγ induces leptin production to enhance satiation in the central nervous system 
(CNS), as well as the release of adiponectin to promote fatty acid oxidation in the 
liver. The dual regulation of central and peripheral responses creates the needed 
coordination to maintain metabolic balance.
Given the critical roles of the aforementioned NRs in cellular nutrient sensing, it is 
perhaps not surprising that some of these NRs have been shown to produce hormone- 
like molecules (Fig. 1). To date, two classes of secreted molecules have been promi-
nently linked with these NRs: the fibroblast growth factors (FGFs) and lipids.
 Fibroblast Growth Factors
Screening for genes activated by nutrient-sensing NRs identified several FGFs as 
highly induced [32, 33] (Table 2). There are 22 FGFs (FGF1–FGF23) in the human 
genome (FGF15 is the mouse ortholog of human FGF19 [34]) that are classified as 

























Fig. 1 Integrative physiology through nuclear receptor (NR)–mediated crosstalk. Nutrient-sensing 
NRs amplify or propagate nutrient signals through local and long-range hormone actions. In the 
fed state, intestinal farnesoid X receptor (FXR) activation resulting from bile acid release produces 
fibroblast growth factor (FGF) 15/19. FGF15/19 limits hepatic bile acid synthesis and promotes 
glycogen and protein synthesis to store nutrients. Postprandial carbohydrate and lipid influx 
activate a hepatic peroxisome proliferator-activated receptor (PPAR) δ–controlled lipid synthesis 
program. The phosphocholine PC(18:0/18:1) is secreted as a long-range hormone to promote 
muscle fat utilization. Feeding activates adipose tissue PPARγ, which, in turn, controls the release 
of multiple adipokines. Locally, FGF21 amplifies PPARγ signaling and promotes further adipo-
genesis. FGF1 is another paracrine signal that is essential for healthy adipose tissue remodeling 
and for maintaining whole-body insulin sensitivity. Systemically, adiponectin enhances lipid 
 oxidation in muscle and liver, whereas leptin increases satiation by acting on the central nervous 
system. During fasting, hepatic PPARα activation secretes FGF21, whose pleiotropic effects, 
including elevated adipose tissue lipolysis and hepatic ketogenesis, are important for adaptive 
 fasting response. In addition, FGF21 interferes with the circadian clock in the brain and modulates 
physical activities
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proteins that interact locally with fibroblast growth factor receptors (FGFRs) as 
autocrine/paracrine factors to modulate cell growth, angiogenesis and wound 
 healing [34]. In contrast, the endocrine FGFs (FGF15/19, FGF21, and FGF23) bind 
heparan sulfate poorly, thereby escaping the extracellular matrix to circulate in the 
blood. Furthermore, the endocrine FGFs require α- and β-klotho co-receptors for 
signal transduction.
After consuming a meal, the liver takes up 25–35 % of dietary carbohydrates 
[35]. This effect cannot be replicated by either systemic hyperglycemia or hyperin-
sulinemia, suggesting that crosstalk between the gastrointestinal tract and liver is 
critical for hepatic glucose utilization. More importantly, feeding-induced hepatic 
glycogen synthesis remains functional in a genetic model that lacks insulin signal-
ing in the liver [36, 37], raising the possibility of a parallel pathway to control 
postprandial hepatic metabolic reprogramming. Postprandial bile acid release and 
subsequent reabsorption are integral responses to feeding. The reabsorption of bile 
acids in the intestine leads to the activation of intestinal FXR and the subsequent 
secretion of FGF15/19, a direct target of FXR. Originally found to suppress hepatic 
de novo synthesis of bile acids [32], FGF15/19 has recently been found to promote 
hepatic glycogen synthesis and protein synthesis by activating the Ras–extracellular 
signal-related kinase (ERK) pathway, a parallel pathway to the insulin-activated 
PI3K–AKT pathway [38]. These findings implicate FGF15/19 in the coordination 
of intestinal feeding responses with hepatic metabolic changes.
In the fasted state, the coordinated activation of hepatic fatty acid oxidation and 
white adipose tissue lipolysis constitutes a major axis of energy substrate switch from 
carbohydrate to lipids. FGF21, a hepatic PPARα target gene, was found to play impor-
tant roles in liver-adipose crosstalk during fasting [33, 39]. As serum levels of FGF21 
correlate closely with hepatic FGF21 expression [40], the liver is thought to be the 
major source of circulating FGF21. FGF21 promotes free fatty acid release from white 
adipose tissue by activating several lipases, thereby providing substrates for hepatic 
fatty acid oxidation and ketogenesis. In addition, FGF21 enhances hepatic ketogenesis 
through increasing the protein levels of rate-limiting enzymes in ketogenesis.
However, the adaptive fasting response, especially after prolonged fasting, 
requires the coordinated actions of all major organs to enhance survival. Recently, 
FGF21 was found to suppress physical activity, alter circadian behavior, and reduce 
female fertility [41, 42]—actions known to be involved in the physiological response 
to prolonged fasting. Moreover, these adaptive responses were attributed to FGF21 
activity in the suprachiasmatic nucleus (SCN) region of the brain.
Table 2 Nutrient-regulated 
fibroblast growth factors 
(FGFs)





FXR farnesoid X receptor, PPAR peroxisome proliferator- 
activated receptor
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Interestingly, pharmacological administration of FGF21 elicits pleiotropic effects 
beyond the changes seen in the adaptive fasting response [43, 44], suggesting addi-
tional roles of FGF21 in other physiological settings. Indeed, FGF21 was found to 
be a target of PPARγ in adipose tissue, where its paracrine actions potentiate PPARγ 
activation in the postprandial state [40]. Notably, the effects of FGF21 on glucose 
homeostasis and hepatic lipid metabolism were shown to be dependent on adipo-
nectin, a PPARγ-induced adipokine [44].
In addition to liver and white adipose tissue, FGF21 is produced in brown fat 
[45] and skeletal muscle [46] in response to specific stimuli, suggesting that FGF21 
coordinates the tissue-specific responses of the major metabolic organs.
The expressions of FGF15/19 and FGF21 are exquisitely dynamic during fasting 
and feeding cycles [32, 33, 40, 47]. The nutrient-responsive nature of FGF21 and 
FGF15 expression opens a new chapter for their respective roles in metabolism. In 
contrast, the prototypic FGF1 and FGF2 [34] are ubiquitously expressed [48], with 
established roles in wound healing and brain development [34]. Whereas FGF2 
knockout mice have mild brain development and wound healing defects, FGF1 
knockout mice are phenotypically normal [49]. In search of additional FGFs that 
may act as nutrient-controlled hormones, FGF1 was found to be highly induced 
in white adipose tissue upon feeding of a high-fat diet [50]. Conversely, FGF1 
knockout (FGF1KO) mice developed marked adipose tissue fibrosis, impaired 
glucose homeostasis, and insulin insensitivity when fed a high-fat diet. Furthermore, 
upon withdrawal of the high-fat diet, FGF1KO mice developed pronounced fat 
necrosis. Given that adipose tissue expansion accompanied by increased vascular-
ization is required to maintain insulin sensitivity under conditions of nutrient  surplus 
[51], the poor white adipose tissue vascularization observed in FGF1 knockout mice 
may be responsible for their severe insulin-resistant phenotype on a high-fat diet. 
Interestingly, FGF1 is shown to be directly regulated by PPARγ, and PPARγ and its 
target genes are increased in FGF1 knockout mice [50]. Therefore, FGF1 appears to 
be an essential output for PPARγ-mediated insulin sensitization. Distinct from 
FGF21-mediated amplification of PPARγ-mediated adipogenesis and adipokine 
production [40], FGF1 does not promote adipogenesis in 3 T3-L1 cells [52]. These 
properties raise the intriguing possibility of recombinant FGF1 (rFGF1) as an 
antidiabetic drug that may minimize the side effects associated with the thiazoli-
dinedione class of PPARγ agonists. Indeed, rFGF1 injection markedly improves 
insulin sensitivity in genetic and diet-induced obesity models [53]. These effects are 
insulin dependent, suggesting a role as an insulin sensitizer, and require adipose 
FGFR1 expression, as rFGF1 fails to lower blood glucose in FGFR1 adipose–
specific knockout mice. Interestingly, rFGF1 treatment does not alter adipose tissue 
vasculature, indicating differences between pharmacological administration and 
genetic studies. Importantly, an N-terminally truncated FGF1 analog with markedly 
reduced mitogenic activity was similarly able to normalize blood glucose levels in 
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diabetic mice [53]. The ability to dissociate the mitogenic and glucose-lowering 
activities of FGF1 suggests that these different effects may be receptor specific. 
Nevertheless, these results demonstrate that FGF1 is a critical mediator of nutrient 
responsiveness in adipose tissue and has significant therapeutic potential.
 Lipids
De novo lipogenesis has emerged as a novel pathway that produces lipid signaling 
molecules, including NR ligands. It was found that activation of PPARδ in the 
liver enhanced hepatic de novo lipogenesis but paradoxically reduced serum lipid 
concentrations [6, 29]. The reduction of serum lipids was also correlated with 
increased fatty acid uptake and oxidation in the skeletal muscle. Through unbiased 
metabolomics profiling, phosphocholine PC(18:0/18:1) was identified as a signaling 
molecule that facilitates postprandial crosstalk between the liver and muscle to pro-
mote fatty acid utilization. Furthermore, the effects of PC(18:0/18:1) are mediated 
by another NR, PPARα, in the muscle, underlying a new model of tissue crosstalk 
through NRs.
 Concluding Remarks
In 1995, 10 years after the cloning of the first NR, the glucocorticoid receptor, the 
challenge of the field was proposed: “…to elucidate the contributions of these 
 individual systems to the integrated and complex processes associated with the 
multihormonal nature of metabolic regulation…” [54] This review summarizes our 
current understandings toward this challenge. An immediate implication of our 
expanded knowledge of endogenous ligands and downstream hormonal signals is to 
explore their potential as novel therapeutics. Indeed, several compounds are in clinical 
trials for metabolic syndrome. In addition, these recent advances have highlighted 
the role of nutrient-sensing NRs in coordinating metabolic homeostasis. Through 
receptor activation, environmental cues are transduced as local metabolic outputs 
and long-range hormonal actions (Fig. 2). In a reductionist’s perspective, these 
receptors may be important on–off switches for specific physiological states [55]. 
While wholesale, prolonged activation of any of these receptors may not be desirable, 
the use of high-affinity synthetic ligands offers a window to tease out beneficial 
downstream targets, especially in light of the identification of several hormone-like 
molecules that are good therapeutic candidates. With readily available synthetic 
ligands and mouse genetic models, it is possible that these receptors will become 
platforms for drug discovery.
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Fig. 2 Nuclear receptors (NRs) as hubs to transduce environmental signals into daily metabolic 
rhythms. Originally identified as sensors for lipophilic nutrients to control their respective ligand 
metabolism, emerging evidence points to an integrative nature of the regulation and action of the 
peroxisome proliferator-activated receptor (PPAR), farnesoid X receptor (FXR), and liver X recep-
tor (LXR) families of NRs. In addition to nutrients, their activities are fine-tuned by endogenous 
ligands and the circadian clock. Activation of these NRs not only controls key cellular metabolic 
programs but also produces hormones that further connect metabolic tissues for a cohesive 
response to nutrient flux. Given the central roles of NRs in nutrient signaling, several pharmaco-
logical agents have been developed or are in development for metabolic diseases. Additionally, the 
NR-controlled hormones represent yet another emerging venue for therapeutics
S. Liu et al.
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